Amulya Gottiparthy
Athens, GANPI 1972000842
Payments from drug & device makers
$2,663in general payments, 2019–2025
Across 129 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$419
- AbbVie$370
- Genentech USA, Inc.$307
- UCB, Inc.$303
- CSL Behring$210
- Takeda Pharmaceuticals U.S.A., Inc.$161
- plus $893 from 11 others
What the payments were for
- Food & beverage$2,663100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
21
22
23
24
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 21 | $419 |
| AbbVie | 20 | $370 |
| Genentech USA, Inc. | 17 | $307 |
| UCB, Inc. | 11 | $303 |
| CSL Behring | 9 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $161 |
| Argenx US, Inc. | 6 | $152 |
| Biogen | 8 | $129 |
| EMD Serono, Inc. | 6 | $107 |
| Novartis | 5 | $101 |
| Acadia Pharmaceuticals Inc | 4 | $91 |
| Sanofi | 4 | $83 |
| Johnson & Johnson | 3 | $65 |
| Pfizer | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Grifols USA, LLC | 1 | $13 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.